11/14/2013 10:06:52 AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter ended September 30, 2013.
“The third quarter of 2013 was a productive one for us,” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “We not only advanced our lead antibiotic candidate eravacycline into pivotal clinical trial development, with the start of a Phase 3 clinical trial for the treatment of complicated intra-abdominal infections, but also confirmed details of our second Phase 3 trial, which will involve IV-to-oral step-down of eravacycline in the treatment of complicated urinary tract infections.
Help employers find you! Check out all the jobs and post your resume.
comments powered by